Jacobio Entered into a Clinical Collaboration with Merck to Evaluate JAB-BX102 + Keytruda (pembrolizumab) for Solid Tumors
Shots:
- The companies collaborated to evaluate JAB-BX102 + Keytruda (anti-PD-1 therapy) in the clinical study for advanced solid tumors
- The study focuses to evaluate the clinical effect of JAB-BX102 + Keytruda & will provide new treatment options to patients. The published clinical data of the combination therapy showed prolonged survival of patients with NSCLC
- JAB-BX102 is a humanized CD73 mAb that has been developed by Jacobio & granted approvals for clinical trials in the US & China in Oct 2021 & Mar 2022. The company initiates the P-I/IIa study of JAB-BX102 to evaluate the safety, tolerability, PK & preliminary anti-tumor efficacy of JAB-BX102 as monotx. & in combination with pablizumab for advanced solid tumors in China & the US
Ref: Jacobio | Image: Jacobio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
